This paper is only available as a PDF. To read, Please Download here.
Abstract
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are a class of oral glucose-lowering
agents commonly used for the treatment of type 2 diabetes (T2D). With increased use
there has been an increase in the incidence of the rare but life-threatening complication
of euglycemic diabetic ketoacidosis. A common but underappreciated precipitant is
colonoscopy. This review outlines the pathophysiology of the interaction between colonoscopy
and SGLT2i use, the evidence regarding SGLT2i use in the periprocedural setting and
society guidelines.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of DiabetesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Accepted:
December 19,
2022
Received in revised form:
October 26,
2022
Received:
July 31,
2022
Publication stage
In Press Journal Pre-ProofFootnotes
There author do not have any conflicts of interest.
Identification
Copyright
© 2022 Canadian Diabetes Association.
